Correlation Between Innovent Biologics and Crinetics Pharmaceuticals

Can any of the company-specific risk be diversified away by investing in both Innovent Biologics and Crinetics Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Innovent Biologics and Crinetics Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Innovent Biologics and Crinetics Pharmaceuticals, you can compare the effects of market volatilities on Innovent Biologics and Crinetics Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Innovent Biologics with a short position of Crinetics Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Innovent Biologics and Crinetics Pharmaceuticals.

Diversification Opportunities for Innovent Biologics and Crinetics Pharmaceuticals

-0.34

Correlation Coefficient

Innovent Biologics  Crinetics Pharmaceuticals

Very good diversification

The 3 months correlation between Innovent and Crinetics is -0.34. Overlapping area represents the amount of risk that can be diversified away by holding Innovent Biologics and Crinetics Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Crinetics Pharmaceuticals and Innovent Biologics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Innovent Biologics are associated (or correlated) with Crinetics Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Crinetics Pharmaceuticals has no effect on the direction of Innovent Biologics i.e., Innovent Biologics and Crinetics Pharmaceuticals go up and down completely randomly.

Pair Corralation between Innovent Biologics and Crinetics Pharmaceuticals

Assuming the 90 days horizon Innovent Biologics is expected to generate 1.15 times more return on investment than Crinetics Pharmaceuticals. However, Innovent Biologics is 1.15 times more volatile than Crinetics Pharmaceuticals. It trades about 0.1 of its potential returns per unit of risk. Crinetics Pharmaceuticals is currently generating about -0.15 per unit of risk. If you would invest  475.00  in Innovent Biologics on December 30, 2024 and sell it today you would earn a total of  115.00  from holding Innovent Biologics or generate 24.21% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	95.38%
Values	Daily Returns

Innovent Biologics  vs.  Crinetics Pharmaceuticals

Innovent Biologics

Risk-Adjusted Performance

OK

Compared to the overall equity markets, risk-adjusted returns on investments in Innovent Biologics are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. Despite nearly fragile basic indicators, Innovent Biologics reported solid returns over the last few months and may actually be approaching a breakup point.

Crinetics Pharmaceuticals

Risk-Adjusted Performance

Very Weak

Over the last 90 days Crinetics Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Pair Trading with Innovent Biologics and Crinetics Pharmaceuticals

The main advantage of trading using opposite Innovent Biologics and Crinetics Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Innovent Biologics position performs unexpectedly, Crinetics Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Crinetics Pharmaceuticals will offset losses from the drop in Crinetics Pharmaceuticals' long position.

The idea behind Innovent Biologics and Crinetics Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.